Anticancer agent 47 (compound 4j) exhibits potent anticancer properties, demonstrating antiproliferative activities and inducing apoptosis as well as cell cycle arrest at G0/G1 phase. Moreover, Anticancer agent 47 has exhibited significant in vivo antitumor activities [1].

Anticancer agent 47 (compound 4j) shows antiproliferative activities with IC 50 s of 1.6, 0.72, 7.07 μM for HepG2, A549, H596 cells, respectively [1]. Anticancer agent 47 (0.8, 1.6, 3.2 μM; 24 h) induces apoptosis and cell cycle arrest at G0/G1 phase [1]. Anticancer agent 47 (5 μM; 5h) significantly increases ROS production [1]. Apoptosis Analysis [1] Cell Line: HepG2, H596 cells Concentration: 0.8, 1.6, 3.2 μM Incubation Time: 24 h Result: Induced apoptosis with the apoptotic cell rates were 14.23, 20.47 and 27.66% at 0.8, 1.6, 3.2 μM in HepG2 cell, respectively. Cell Cycle Analysis [1] Cell Line: HepG2 cells Concentration: 0.8, 1.6, 3.2 μM Incubation Time: 24 h Result: Showed 48.54%, 49.60% and 53.00% cells were at G0/G1 phase at 0.6, 1.2 and 2.4 μM, respectively.

Anticancer agent 47 (20 mg/kg; i.v.; once every 2 days for 19 days) shows antitumor activities [1]. Animal Model: BALB/c nude mice (HepG2 xenografts) [1] Dosage: 20 mg/kg Administration: I.v.; once every 2 days for 19 days Result: Effectively inhibited tumor growth with the 58.7% tumor inhibition rate.